Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149871 (
deep vein thrombosis
)
12,364
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The optimum conditions for labelling platelets with lipophilic 99mTc-hexamethyl propylene amine oxime (99mTc-HMPAO) were evaluated. An aseptic closed system was used throughout the procedure in patient studies. 48 ml blood were withdrawn into 12 ml
ACD
using sterile 60 ml plastic syringes. After mixing, the blood was transferred to sterile 10 ml vacuum tubes and platelets were isolated according to standard centrifugation procedures. The labelling efficiency was not dependent upon incubation temperature (22 degrees C, 37 degrees C) but was greater in saline than in the presence of plasma. The labelling efficiency increased with time up to 60 min in saline. The elution of 99mTc from platelets was about 25% in plasma milieu in vitro but did not increase with time during 160 min. 5 patients with verified fresh
deep vein thrombosis
in the lower leg were imaged after injection of labelled autologous platelets. All 4 of the patients without anticoagulant therapy showed positive uptake of 99mTc-HMPAO-labelled platelets, but the 5th patient--under heparin therapy--was negative in scintigraphy. Our results are encouraging and 99mTc-HMPAO-labelled platelets offer a promising tool for evaluating various clinical situations.
...
PMID:Radiolabelling of human platelets with 99mTc-HMPAO. 273 95
Pathologic fractures of the femur because of bone metastases seriously affect the quality of life of cancer patients. Different surgical options are indicated to achieve a durable and solid fixation, depending on several clinical, prognostic and mechanical factors. Locked intramedullary nailing is currently used to treat pathologic femoral fractures in patients with multiple metastases when the trochanteric region or shaft is mainly involved. This study evaluates intramedullary nailing for treatment of patients with pathologic femoral fractures, focussing on complications, clinical and functional outcomes and survival rates. The series included 80 pathologic fractures treated with a titanium alloy Proximal Nail (Standard or Antirotation) or Lateral Anterograde Femoral Nail (PFN, PFNA or LAFN, Synthes) inserted in a locked static mode. Acrylic cement was used to fill the bone cavity after nail insertion in eight patients; percutaneous cementoplasty was simultaneously performed in 11 cases of severe ipsilateral acetabular osteolysis. Postoperative outcomes focussed on pain relief, postoperative mobility and quality of life and they were analysed retrospectively using QOL-
ACD
and ECOG. Eleven patients (13.75%) suffered from non-fatal
DVT
post-surgery, with no pulmonary embolism. Six patients (7.5%) developed superficial wound infections and two patients (2.5%) developed pnaeumonia. There was no loss of reduction, breakage, screw pull out, or hardware or implant failure that required component substitution or revision. Lung histotype and the contemporary presence of cerebral and visceral metastases appeared to be predisposing factors in reducing survival time. All patients attained satisfactory pain relief, early deambulation and a marked clinical improvement during the first 6-10 postoperative months, with gradual worsening thereafter from deterioration of their general condition due to cancer progression. The patients' survival rate was 40% at 1 year, 25% at 2 years and 15% at 3 years. Results confirm that multiple factors related to patients and primary cancer may affect survival rate after femoral fracture. Intramedullary nailing should be indicated for pathologic fractures at femoral diaphysis and metaphysis when cancer is in an advanced stage. This procedure offers good and durable stability, and enables pain relief, early postoperative mobilisation and weight-bearing, thus improving the quality of life of cancer patients.
...
PMID:Intramedullary nailing for treatment of pathologic femoral fractures due to metastases. 2411 52